Foltynie, Thomas

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 2,454

Adaptive deep brain stimulation in advanced Parkinson disease.

Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., Foltynie, T., Limousin, P., Ashkan, K., FitzGerald, J., et al. (2013) · Annals of Neurology

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 1,374

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 889

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 529

Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease

Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain

Lysosomal Storage Disorders ResearchParkinson's Disease Mechanisms and Treatments

Cited by 433

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 383

Stimulating at the right time: phase-specific deep brain stimulation

Cagnan, H., Pedrosa, D., Little, S., Pogosyan, A., Cheeran, B., Aziz, T., Green, A., Fitzgerald, J., Foltynie, T., Limousin, P., et al. (2017) · Brain

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 270

Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson’s disease

Akram, H., Sotiropoulos, S. N., Jbabdi, S., Georgiev, D., Mahlknecht, P., Hyam, J., Foltynie, T., Limousin, P., De Vita, E., Jahanshahi, M., et al. (2017) · NeuroImage

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 263

Cognitive Deficits and Psychosis in Parkinson???s Disease: A Review of Pathophysiology and Therapeutic Options

Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 147

The Impact of Type 2 Diabetes in Parkinson's Disease

Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 132

Subthalamic nucleus deep brain stimulation in parkinson's disease: the effect of varying stimulation parameters

Dayal, V., Limousin, P., & Foltynie, T. (2017) · Journal of Parkinson’s Disease

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 108

The nature of tremor circuits in parkinsonian and essential tremor

Cagnan, H., Little, S., Foltynie, T., Limousin, P., Zrinzo, L., Hariz, M., Cheeran, B., Fitzgerald, J., Green, A. L., Aziz, T., et al. (2014) · Brain

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 97

Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation

Cagnan, H., Brittain, J.-S., Little, S., Foltynie, T., Limousin, P., Zrinzo, L., Hariz, M., Joint, C., Fitzgerald, J., Green, A. L., et al. (2013) · Brain

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 95

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Vijiaratnam, N., Girges, C., Auld, G., Chau, M., Maclagan, K., King, A., Skene, S., Chowdhury, K., Hibbert, S., Morris, H., et al. (2021) · BMJ Open

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 84

A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease

Payne, T., Appleby, M., Buckley, E., van Gelder, L. M. A., Mullish, B. H., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S. W., McNeill, A., et al. (2023) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 76

Genome-wide determinants of mortality and motor progression in Parkinson’s disease

Tan, M. M. X., Lawton, M. A., Pollard, M. I., Brown, E., Real, R., Carrasco, A. M., Bekadar, S., Jabbari, E., Reynolds, R. H., Iwaki, H., et al. (2024) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 17